INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Oles	
Art Unit		
Examiner Name		
Attornov Docket Numb	or.	65925 0121

Examiner   Cite   Patent Number   Code   Issue Date   Name of retented of Application Relevant Passages or Rel										
Examiner Cite Publication Number Kind Code! Date Officed Document Pages, Columns, Lines who related to the Add button.    September   Pages, Columns, Lines who related became the Relevant Passages or Rel Figures Appear										
Examiner   Cite   Patent Number   Code   Issue Date   Name of retented of Application Relevant Passages or Rel					U.	S.PATENTS			Remove	_
2   6791723   B1   2004-09-14   Valimago et al			Patent Number				Relevant Passages or Rel			
If you wish to add additional U.S. Patent citation information please click the Add button.		1	6750988	B1	2004-06-15	Ghislain et al	ı			
U.S.PATENT APPLICATION PUBLICATIONS  Examiner Cite Publication Number Kind Code! Date of cited Document of cited Document  1 20000085840 A1 2002-07-04 Lebenow  If you wish to add additional U.S. Published Application citation information please click the Add button. Add  FOREIGN PATENT DOCUMENTS  Remove		2	6791723	B1	2004-09-14	Vallmajo et a				
Examiner Cite Publication Number Kind Code! Date Name of Patentee or Applicant Relevant Passages or Rel  1 2002008540 A1 200207-04 Lebenow  If you wish to add additional U.S. Published Application citation information please click the Add button. Add  FOREIGN PATENT DOCUMENTS  [Ramove]	If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	Add button.		Add	_
Lexaminer (Life   Publication Number   Nand   Date   Date   Date   Publication Number   Publication Number   Publication Number   Publication Number   Publication Number   Publication   Publication				U.S.P	ATENT APP	LICATION PUE	LICATIONS		Remove	
If you wish to add additional U.S. Published Application citation information please click the Add button Add FOREIGN PATENT DOCUMENTS Remove					Releva	ant Passages or Rele				
FOREIGN PATENT DOCUMENTS Remove		1	20020085840	A1	2002-07-04	Liebenow				
TOREIGN FATER BOOMERTO	If you wis	h to a	dd additional U.S. Publ	lished Ap	polication cital	ion information	please click the Ar	d buttor	Add	_
					FOREIGN P	ATENT DOCUM	MENTS		Remove	_
Name of Patentee or							Applicant of cite	d d	Passages or Relevan	
1		1								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add	If you wis	h to a	 nd additional Foreign F	atent Dr	cument citati	on information r	l alease click the Ad	d button	Add	_
NON-PATENT LITERATURE DOCUMENTS Remove	,		aa aaaaaaaa i oloogii i							

	Application Number		
NEODWATION DIGGS COURT	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor	Oles	
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	or	65825,0131

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

# Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at Iwen USPTO\_GDV or MPEP 901.04. 2 Enter office that issued the document, by the In-clearing code (WIPO Standard ST3.). 3 Fee Implanees patent documents, the advantage on the parent of the Emperor unsprinced the seast include of the patent of the patent of the patent of the patent or the Colument by the appropriate symbols as advantaged on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark then if Employin languages the residence is attached.

# Application Number Filing Date Filing Date Filing Date First Number Invalid Number Filing Date First Number Invalid Number Inv

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	1.98 to make the appropriate selection(s):
----------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Matthew J Booth/	Date (YYYY-MM-DD)	2006-04-24
Name/Print	Matthew J Booth	Registration Number	35454

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.